Imunon, Inc.

$2.13-4.48%($-0.10)
TickerSpark Score
54/100
Mixed
80
Valuation
20
Profitability
60
Growth
80
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMNN research report →

52-Week Range0% of range
Low $2.08
Current $2.13
High $41.22

Companywww.imunon.com

Imunon, Inc. , a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.

CEO
Stacy R. Lindborg
IPO
1999
Employees
25
HQ
Lawrenceville, NJ, US

Price Chart

-67.92% · this period
$37.65$19.89$2.13May 20Nov 18May 20

Valuation

Market Cap
$5.37M
P/E
-0.73
P/S
0.00
P/B
3.19
EV/EBITDA
-0.11
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-341.23%
ROIC
-346.77%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-14,495,000 · 22.15%
EPS
$-6.83 · 67.63%
Op Income
$-14,650,694
FCF YoY
24.93%

Performance & Tape

52W High
$41.22
52W Low
$2.08
50D MA
$2.88
200D MA
$4.09
Beta
2.03
Avg Volume
90.91K

Get TickerSpark's AI analysis on IMNN

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Jan 15, 26CHURCH JEFFREY WAYNEother0
Jan 2, 26CHURCH JEFFREY WAYNEother5,000
Aug 4, 25CHURCH JEFFREY WAYNEother167
Jan 2, 26Bragg Kimberlyother9,050
Jan 2, 26Anwer Khursheedother15,736
Jan 2, 26Fritz Frederick J.other5,892
Jan 2, 26Faller Douglas Vincentother12,667
Jan 2, 26Eylward Susanother8,251
Jan 2, 26Pellizzari Christine Aother4,827
Jan 2, 26Braun Donald Pother5,881

Our IMNN Coverage

We haven't published any research on IMNN yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate IMNN Report →

Similar Companies